June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Riboswitch-mediated modulation of transgene expression following rAAV delivery to the mouse retina
Author Affiliations & Notes
  • Chris Reid
    Ophthalmology, Medical College of Wisconsin, New Berlin, Wisconsin, United States
  • Daniel M Lipinski
    Ophthalmology, Medical College of Wisconsin, New Berlin, Wisconsin, United States
  • Footnotes
    Commercial Relationships   Chris Reid, None; Daniel Lipinski, None
  • Footnotes
    Support  None
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 4088. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Chris Reid, Daniel M Lipinski; Riboswitch-mediated modulation of transgene expression following rAAV delivery to the mouse retina. Invest. Ophthalmol. Vis. Sci. 2017;58(8):4088.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Recombinant adeno-associated virus (rAAV) vectors have emerged as promising tools for mediating gene therapy for diseases of the retina. Effectively controlling gene expression levels following vector delivery is paramount to the success of potential gene therapies, where uncontrolled over-expression of the therapeutic transgenes can lead to toxicity. Traditionally, inducible promoter systems have been employed. Unfortunately, due to the limited coding capacity of AAV, and the large size of elements required to make such systems work effectively, their inclusion is frequently not practical. Here, we evaluate the use of small (~100bp) ligand responsive self-cleavable riboswitches to modulate gene expression in the mouse retina.

Methods : Six riboswitches were evaluated in HEK293T cells to determine optimal copy number (largest dynamic range) and dose-responsiveness to its activating ligand using a dual luciferase assay. Next, the optimal copy number of each riboswitch was cloned into a rAAV GFP reporter cassette and packaged in an AAV2 capsid. Each GFP-riboswitch cassette was intravitreally injected into C57Bl/6j mice in combination with an AAV2 control vector harboring a non-inducible mCherry reporter gene. Four weeks post-injection, mCherry and GFP fluorescence levels were quantified in vivo using a custom confocal scanning laser ophthalmoscope (cSLO). Mice subsequently received a 1000mg/kg dose of its activating ligand, and fluorescence levels were quantified 2 and 24 hours post-gavage.

Results : Cell culture experiments revealed significant changes in luminescence in response to dosing of the appropriate ligand (p<0.01). In vivo results demonstrated dosing mice with the activating ligand of each riboswitch could achieve a highly significant change in GFP fluorescence at 2 hours post-gavage compared to pre-treatment levels (p<0.01). Importantly, GFP fluorescence was recovered to pre-treatment levels 24 hours after dosing

Conclusions : All riboswitch constructs were capable of modulating transgene expression in vivo. Concurrent dual color cSLO imaging allowed riboswitch-mediated changes in GFP fluorescence to be normalized (to mCherry), effectively standardizing our in vivo measurements. Due to their small size and lack of immunogenicity, incorporation of riboswitches in rAAV constructs could have potential clinical applications where tightly controlled gene expression is paramount.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×